GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Completed
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: The Yale Stress Center: Yale University, New Haven, Connecticut
Conditions: Obesity
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
Completed
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
04/13/2022
Locations: Yale University School of Medicine, New Haven, Connecticut
Conditions: Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Completed
Albiglutide is an analogue of glucagon-like peptide-1 (GLP-1), used to treat type 2 diabetes This study will test whether albiglutide affects the occurrence of major cardiovascular events such as heart attacks or strokes and other important medical outcomes in persons with type 2 diabetes, when used alone or added to other diabetes treatments.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
02/11/2019
Locations: GSK Investigational Site, New Haven, Connecticut
Conditions: Diabetes Mellitus
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
Completed
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/21/2016
Locations: GSK Investigational Site, New Britain, Connecticut +2 locations
Conditions: Diabetes Mellitus, Type 2
Safety and Efficacy of Albiglutide in Type 2 Diabetes
Completed
The purpose of this study is to determine the safety, tolerability and efficacy of albiglutide in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, New Britain, Connecticut +2 locations
Conditions: Diabetes Mellitus, Type 2
Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
Completed
The purpose of this study is to determine if albiglutide is safe and effective in the treatment of type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, New Britain, Connecticut +2 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes
Completed
A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, New Britain, Connecticut +2 locations
Conditions: Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
Completed
The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, New Britain, Connecticut +2 locations
Conditions: Diabetes Mellitus, Type 2
Safety and Efficacy Study of Albiglutide in Type 2 Diabetes
Completed
The purpose of this study is to determine whether albiglutide is effective in the treament of patients with type 2 diabetes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/18/2016
Locations: GSK Investigational Site, New Britain, Connecticut
Conditions: Diabetes Mellitus, Type 2
Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only
Completed
This study is a placebo-controlled study in patients with Type 2 Diabetes Mellitus who are either taking no diabetes medication or who are taking metformin only. This study will investigate the safety, tolerability, and efficacy of Albiglutide (GSK716155) and will measure the levels of Albiglutide (GSK716155) in the bloodstream when it is given for 16 weeks. As a comparison, some subjects will receive exenatide instead of Albiglutide (GSK716155). The study will involve weekly visits for 17 weeks... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
11/03/2016
Locations: GSK Investigational Site, Trumbull, Connecticut
Conditions: Diabetes Mellitus, Type 2